InvestorWire NewsRoom

Article

CannAssist International Corp. (CNSC) Proprietary Tech Is Core of CBD Products with Better Absorption
February 2, 2021

CannAssist International Corp. (CNSC) Proprietary Tech Is Core of CBD Products with Better Absorption

  • Absorption vital component of product effectiveness
  • CNSC’s proprietary CiBiDinol technology is cannabidiol made water compatible
  • Xceptol products offer CBD in format more in line with body’s natural bioactivity

CannAssist International (OTCQB: CNSC) is a biotechnological pharmaceutical and wellness company marketing its exclusive Xceptol consumer brand. The company is the owner of Xceptor Labs, which uses proprietary technology to create Xceptol CBD products. The company complex has better absorption than currently marketed oil-based products — a key advantage when assessing products’ effectiveness.

Drug absorption, or the way a drug is absorbed into the bloodstream, is a vital component in the effectiveness of treatments for a wide variety of diseases and disorders (https://ibn.fm/NlIT3). A product that claims some of the fastest rates on the market is worth paying attention to.

Numerous factors can impact the absorption of a drug into the body, including solubility, drug formulation, administration route, and gastric emptying rate. These are all factors carefully evaluated by CannAssist, which utilizes its proprietary technology — CiBiDinol — in the formulation of its products and offering that technology to third-party providers.

Developed by CannAssist founder Mark Palumbo and available through CNSC’s Xceptor Labs, CiBiDinol technology is cannabidiol made water compatible (https://ibn.fm/iHNsR). CiBiDinol addresses critical issues regarding CBD molecules, including delivery, bioavailability and short shelf life, by offering predictable potency, reduced dosage requirements and a wider variety of product forms. The company’s innovative process combines CBD molecules with penetration-enhancing cyclodextrin, altering the CBD molecule’s surface and rendering it water dispersible. This technology improves absorption through the skin, mucosa and gut; it also enables administration through friendly dosage forms such as capsules, drops, creams and drinks.  

CannAssist notes that the technology provides CBD in a format that is more in line with the body’s natural bioactivity. Using this unique approach and exclusive technology as the basis for its entire product line, CannAssist offers an essential component for creating CBD products with more predictable potency.

Xceptor Labs uses CiBiDinol in its CBD products, which have better absorption than currently marketed oil-based products. CannAssist launched its exclusive Xceptol product line in September 2020, which initially included its unscented pain cream formulated with CiBiDinol and ingredients with National Drug Codes registered with the FDA. The company has since added capsules and liquid drops to the product line, with plans for pet drops coming soon.

CannAssist, the owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company. Established in May 2017, CannAssist is headquartered in San Diego County, California, and markets its consumer line of cannabidiol (“CBD”) products under the Xceptol brand. CNSC is currently targeting North America, Central America, South America, South Africa, the EU, the UK and the Philippines as viable product markets. The company has established strategic partnerships in sourcing, manufacturing, processing, laboratory, distribution, public relations and legal representation. 

For more information, visit the company’s website at www.CannAssistInternational.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent Articles

Release Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).